<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65302">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717638</url>
  </required_header>
  <id_info>
    <org_study_id>V72P12E2</org_study_id>
    <secondary_id>2011-004931-30</secondary_id>
    <nct_id>NCT01717638</nct_id>
  </id_info>
  <brief_title>Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1</brief_title>
  <official_title>A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a Phase 3 extension of study V72P12E1. The main aim of the second extension study is
      to explore the bactericidal antibody persistence in 4-year-old children after a fourth dose
      boost of rMenB+OMV NZ or after a two-dose catch-up schedule of rMenB+OMV NZ administered to
      toddlers as part of their respective vaccination courses in study V72P12E1.

      In addition, this study will characterize the antibody response to a fifth dose boost in all
      children who received a three-dose primary series of rMenB+OMV NZ at 2, 3, 4 months of age
      (in parent study V72P12), and only in a subset of children who received a three-dose primary
      series of rMenB+OMV NZ at 2, 4, 6 months of age (in parent study V72P12). Antibody response
      will also be characterized to a third dose boost of rMenB+OMV NZ administered at
      approximately 4 years of age in all children who received a two catch-up doses of rMenB+OMV
      NZ as toddlers in study V72P12E1.

      Finally, the safety and immunogenicity of two catch-up doses of rMenB+OMV NZ administered 2
      months apart to healthy naïve children at 4 years of age will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentage of subjects with SBA persistence, hSBA ≥1:5 and hSBA ≥1:4 to N.meningitidis serogroups B</measure>
    <time_frame>Throughout individual subject participation -Groups 1 and 2 subset 1: 1 day; Groups 1 and 2 subset 2 and Groups 3, 4, 5, 6: 1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>To explore antibody persistence in 4-year-old children after a fourth dose boost of rMenB+OMV NZ administered to toddlers in study V72P12E1, who previously received a three-dose primary series of rMenB+OMV NZ as infants in the study V72P12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SBA geometric mean titers (GMT) and geometric mean ratios(GMR) based on GMTs at 1 month after last rMenB+OMV NZ booster dose in V72P12E1 study.</measure>
    <time_frame>Throughout individual subject participation-Groups 1 and 2 subset 1: 1 day; Groups 1 and 2 subset 2 and Groups 3, 4, 5, 6: 1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SBA persistence, hSB ≥1:5 and hSBA ≥1:4 to N. meningitidis serogroups B, SBA GMTs and GMRs based on GMTs at 1 month after last rMenB+OMV NZ booster dose in V72P12E1 study.</measure>
    <time_frame>Throughout individual subject participation - Groups 1 and 2 subset 2 and Groups 3, 4, 5, 6: 1 month; Group 7: 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBA GMTs, percentage of subjects with hSBA ≥ 1:5 and ≥ 1:8, and fourfold increase to each of the four indicator strains.</measure>
    <time_frame>Throughout individual subject participation - Groups 1 and 2 subset 2 and Groups 3, 4, 5, 6: 1 month; Group 7: 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and systemic reactions and Adverse Events</measure>
    <time_frame>For 7 days  after study vaccination with rMenB+OMV NZ</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Local reactions: Pain, erythema, induration, swelling systemic Reactions: Fever [i.e., axillary temperature ≥ 38.0°C], change in eating habits, sleepiness, vomiting, diarrhea, irritability, headache, arthralgia and rash.
Local and systemic reactions and Adverse Events will be collected for 7 days after each vaccination. In addition, Serious Adverse Events, Medically Attended Adverse Events and Adverse Events leading to premature withdrawal will be collected throughout the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">805</enrollment>
  <condition>Meningococcal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>Subset 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-vaccination subset of Groups 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenB+OMV NZ-5th dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination subset of Groups 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: MenB+OMV NZ - 5th dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: MenB+OMV NZ-3rd dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: MenB+OMV NZ-3rd dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: MenB+OMV NZ-3rd dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: MenB+OMV NZ-2 catch-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenB+OMV NZ</intervention_name>
    <description>0.5 mL of rMenB+OMV NZ, Intramuscular, single dose</description>
    <arm_group_label>MenB+OMV NZ-5th dose</arm_group_label>
    <arm_group_label>Group 3: MenB+OMV NZ - 5th dose</arm_group_label>
    <arm_group_label>Group 4: MenB+OMV NZ-3rd dose</arm_group_label>
    <arm_group_label>Group 5: MenB+OMV NZ-3rd dose</arm_group_label>
    <arm_group_label>Group 6: MenB+OMV NZ-3rd dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenB + OMV NZ</intervention_name>
    <description>0.5 mL single dose of rMenB+OMV NZ, Intramuscular, 2 doses 2 months apart</description>
    <arm_group_label>Group 7: MenB+OMV NZ-2 catch-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. Inclusion Criteria for naïve subjects, newly enrolled (Group 7):

          1. 4 years old (48 to 60 months) healthy male and female subjects will be recruited from
             the same sites as in study V72P12E1. The age window is defined as the first day the
             subject turns 4 years old up to the day before the subject turns 5 years old.

          2. For whom parent/legal guardian(s) has given written informed consent after the nature
             of the study has been explained.

          3. For whom parent/legal guardian(s) confirmed availability for the visit(s) scheduled
             in the study.

          4. In good health as determined by medical history, physical examination, clinical
             judgment of the investigator.

        B. Inclusion Criteria for follow-on participants (Groups 1, 2, 3, 4, 5, and 6):

        Inclusion criteria are the same as for Groups 7, with the addition that they are subjects
        who completed the vaccination course of V72P12E1 study.

        Exclusion Criteria:

        A. Exclusion Criteria for naïve subjects, newly enrolled (Group 7):

          1. Subjects whose parents/legal guardians are unwilling or unable to give written
             informed consent to participate in the study.

          2. History of any meningococcal B vaccine administration.

          3. Previous ascertained or suspected disease caused by N. meningitidis.

          4. Household contact with and/or intimate exposure to an individual with laboratory
             confirmed N. meningitidis.

          5. History of allergic reaction to any vaccine component.

          6. Significant chronic infection.

          7. Any serious chronic or progressive disease according to the judgment of the
             investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic
             disease, progressive neurological disease or seizure, either associated with fever or
             as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV
             infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal
             failure or severe malnutrition).

          8. Known or suspected impairment/alteration of the immune system resulting from (for
             example) receipt of chronic immunosuppressive therapy or immunostimulants.

          9. Participation in another clinical trial  within 90 days prior to enrolment or planned
             for during study.

         10. Family members and household members of research staff.

         11. Any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives.

        B. Exclusion Criteria for follow-on participants (Groups 1, 2, 3, 4, 5, and 6):

        Exclusion criteria are the same as for Group 7, with the exception of criterion 2 and
        excluding participation in V72P12E1 for criterion 9.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>48 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jaromer</city>
        <state>Alšova 466</state>
        <zip>55101</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jaromer</city>
        <state>Dr. E.Beneše 191</state>
        <zip>55101</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Sezemice</city>
        <state>Havlickova 168</state>
        <zip>53304</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Hronov</city>
        <state>Hostovského 485</state>
        <zip>54931</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Ceska Skalice</city>
        <state>Husovo namesti 36</state>
        <zip>55203</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Pardubice</name>
      <address>
        <city>Pardubice</city>
        <state>Kyjevska 44</state>
        <zip>53203</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Pardubice</city>
        <state>L.Male 656</state>
        <zip>53012</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Hradec Králové</city>
        <state>Manesova 646</state>
        <zip>50002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biovomed</name>
      <address>
        <city>Hradec Kralove</city>
        <state>Mikolase Alse 639/5</state>
        <zip>50002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Hronov</city>
        <state>Palackeho 517</state>
        <zip>54931</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Hradec Králové</city>
        <state>Pardubicka 752</state>
        <zip>50004</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Chlumec nad Cidlinou</city>
        <state>Pernstynska 127/I</state>
        <zip>50351</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Náchod</name>
      <address>
        <city>Nachod</city>
        <state>Purkynova 446</state>
        <zip>54701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <state>Ruských legií 352</state>
        <zip>37701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Pardubice</city>
        <state>Sladkovskeho 2617</state>
        <zip>53002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <state>Sídliste Vajgar 724/III</state>
        <zip>37701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakulta vojenskeho zdravotnictvi UO</name>
      <address>
        <city>Hradec Kralove</city>
        <state>Trebesska 1575</state>
        <zip>50001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Holice</city>
        <state>U kaplicky 1042</state>
        <zip>53401</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace praktickeho lekare pro deti a dorost</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <state>U nemocnice380/III</state>
        <zip>37701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Firenze -Pediatria</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Cà Granda</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip Pediatria AO Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela A Coruña</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Superior de Investigacion en Salud Publica/Clinica Universitaria San Vicente Martir</name>
      <address>
        <city>Valencia</city>
        <zip>46020/46001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Xeral Cies</name>
      <address>
        <city>Vigo Pontevedra</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Vaccine Group - Centre for Clinical Vaccinology and Tropical Medicine Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Headington</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Georges Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 7, 2013</lastchanged_date>
  <firstreceived_date>October 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal disease, vaccines, children, persistence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
